Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bora Lim

Showing results (51-60 of 147) with videos related to

Pageof 15
Sort By:
Cancer Biology & Therapy|June 25, 2013
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancerBora Lim, Angelique Scicchitano, Cheryl Beachler, et al.
Breast Cancer Research and Treatment|March 4, 2019
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancerJangsoon Lee, Bora Lim, Troy Pearson, et al.
Human Pathology|July 28, 2019
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological featuresQingqing Ding, Hui Chen, Bora Lim, et al.
Oncotarget|May 15, 2015
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Fanny Le Du, Bedrich L Eckhardt, Bora Lim, et al.
Plos One|April 16, 2021
Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic reviewSudpreeda Chainitikun, Jose Rodrigo Espinosa Fernandez, James P Long, et al.
Molecular Cancer Therapeutics|January 16, 2015
A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective AdenovirusYanchun Ma, Sijie Hao, Shuwen Wang, et al.
Biomedicines|July 2, 2021
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi ScreeningJangsoon Lee, Huey Liu, Troy Pearson, et al.
Journal of Pain and Symptom Management|February 17, 2020
Online Couple-Based Meditation Intervention for Patients With Primary or Metastatic Brain Tumors and Their Partners: Results of a Pilot Randomized Controlled TrialKathrin Milbury, Shiao-Pei Weathers, Sania Durrani, et al.
Biochemical and Biophysical Research Communications|June 4, 2017
MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancerNatsuki Sato, Masayuki Wakabayashi, Masatoshi Nakatsuji, et al.
Breast Cancer Research and Treatment|March 1, 2017
Identification of frequent somatic mutations in inflammatory breast cancerNaoko Matsuda, Bora Lim, Ying Wang, et al.
Pageof 15

Showing results (51-60 of 147) with videos related to

Sort By:
Pageof 15
Cancer Biology & Therapy|June 25, 2013
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancerBora Lim, Angelique Scicchitano, Cheryl Beachler, et al.
Breast Cancer Research and Treatment|March 4, 2019
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancerJangsoon Lee, Bora Lim, Troy Pearson, et al.
Human Pathology|July 28, 2019
HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological featuresQingqing Ding, Hui Chen, Bora Lim, et al.
Oncotarget|May 15, 2015
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Fanny Le Du, Bedrich L Eckhardt, Bora Lim, et al.
Plos One|April 16, 2021
Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic reviewSudpreeda Chainitikun, Jose Rodrigo Espinosa Fernandez, James P Long, et al.
Molecular Cancer Therapeutics|January 16, 2015
A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective AdenovirusYanchun Ma, Sijie Hao, Shuwen Wang, et al.
Biomedicines|July 2, 2021
PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi ScreeningJangsoon Lee, Huey Liu, Troy Pearson, et al.
Journal of Pain and Symptom Management|February 17, 2020
Online Couple-Based Meditation Intervention for Patients With Primary or Metastatic Brain Tumors and Their Partners: Results of a Pilot Randomized Controlled TrialKathrin Milbury, Shiao-Pei Weathers, Sania Durrani, et al.
Biochemical and Biophysical Research Communications|June 4, 2017
MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancerNatsuki Sato, Masayuki Wakabayashi, Masatoshi Nakatsuji, et al.
Breast Cancer Research and Treatment|March 1, 2017
Identification of frequent somatic mutations in inflammatory breast cancerNaoko Matsuda, Bora Lim, Ying Wang, et al.
Pageof 15